In parallel, the impact of HCV core on RBP4 expression was assessed by using the tetracycline (tet)-off conditional HCV core transgenic mice with nonobese hepatic steatosis and hypolipidemia [21–24], both phenotypes mimicked HCV-associated metabolic alterations in the human [15]. Here, RBP4 is linked to fatty liver disease.